Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats

British Journal of Pharmacology

Volumn 123, Issue 3, 1998, Pages 405-412

  Zolk, Oliver ^a   Flesch, Markus ^a   Schnabel, Petra ^a   Teisman, Ard C ^b   Pinto, Yigal M ^b   Van Gilst, Wiek H ^b   Paul, Martin ^c   Böhm, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ACE inhibitor; Adenylyl cyclase; Angiotensin II antagonist; G protein; Renin transgenic rat

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENYLATE CYCLASE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR; CYANOPINDOLOL I 125; FORSKOLIN; HYDRALAZINE; ISOPRENALINE; LOSARTAN; MANGANESE; NEUROPEPTIDE Y; PERTUSSIS TOXIN; QUINAPRIL; RENIN;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLOOD PRESSURE; CONTROLLED STUDY; DESENSITIZATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE;

ADENYLATE CYCLASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD PRESSURE; CARDIOMEGALY; GTP-BINDING PROTEINS; HYDRALAZINE; ISOQUINOLINES; LOSARTAN; MYOCARDIUM; NEUROPEPTIDES; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ANGIOTENSIN; TETRAHYDROISOQUINOLINES; VASODILATOR AGENTS;

EID: 0031965345     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701615     Document Type: Article

References (61)

1. AGABITI ROSEI, E., ROMANELLI, G., MUIESAN, M.L., ALICANDRI, C., BESCHI, M., CASTELLANO, M. & MIEUSAN, G. (1984). Impaired response of the hypertrophied left ventricle to β-adrenergic stimulation in hypertensive patients [Abstract]. Circulation, 70 (suppl 2), II-61.
2. ARRIBAS S., SANCHEZ-FERRER C.F., PEIRO C., PONTE A., SALAICES M. & MARIN, J. (1994). Functional vascular renin-angiotensin system in hypertensive transgenic rats for the mouse renin gene Ren-2. Gen. Pharmacol., 25, 1163-1170.
3. BLAUFARB, I.S. & SONNENBLICK, E.H. (1996). The renin angiotensin system in left ventricular remodeling. Am. J. Cardiol., 77, 8C-16C.
4. BÖHM, M., GRÄBEL, C., KNORR. A. & ERDMANN, E. (1995a). Treatment in hypertensive hypertrophy, I. Neuropeptide Y and β-adrenoceptors. Hypertension, 25, 954-961.
5. BÖHM, M., KIRCHMAYR, R. & ERDMANN, E. (1995b). Myocardial Giα-protein levels in patients with hypertensive cardiomyopathy. Cardiovasc. Res., 30, 611-618.
6. BÖHM, M., MOLL, M., SCHMID, B., PAUL, M., GANTEN, D., CASTELLANO, M. & ERDMANN, E. (1994). β-Adrenergic neuroeffector mechanisms in cardiac hypertrophy of renin transgenic rats. Hypertension, 24, 653-662.
7. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72, 248-254.
8. BRUCKSCHLEGEL, G., HOLMER, SR., JANDELEIT, K., GRIMM, D., MUDERS, F., KROMER, E.P., RIEGGER, G.A.J. & SCHUNKERT, H. (1995). Blockade the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension, 25, 250-259.
9. CACHEFEIRO, V., SAKSKIBARA, T & NASJLETTI, A. (1992). Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension, 19, 138-145.
10. CASTELLANO, M. & BÖHM, M. (1997). The cardiac β-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension, 29, 715-722.
11. CECH, S.V. & MAGUIRE, M.E. (1982). Magnesium regulation of the beta-receptor-adenylate cyclase complex. I. Effects of manganese on receptor binding and cyclase activation. Mol. Pharmacol., 22, 267-273.
12. CECH, S.Y., BROADDUS, W.C. & MAGUIRE, ME (1980). Adenylate. cyclase: The role of magnesium and other divalent cations. Mol. Cell. Biochem., 33, 67-92.
13. CLOUGH, D.P., COLLINS, M.G., COMWAY, J., HATTON, R. & KEDDIE, J.R. (1982). Interaction of angiotensin-converting enzyme inhibitors with the function of the sympathetic nervous system. Am. J. Cardiol., 49, 1410-1414.
14. CROZIER, J., IKRAM, H. & AWAN, N. (1995). Losartan in heart failure hemodynamic effects and tolerability. Circulation, 91, 691-697.
15. DAHOLF, B. & HANSSON, L. (1992). Reversal of LVH in hypertensive patients. A metanalysis of 109 treatment studies. Am. J. Hypertens., 5, 95-110.
16. DALAY, P., ROULEAU, J.L., COUSINEAU, D., BRUGESS, J.H. & CHATTERJEE, K. (1986). Effects of captopril and hydralazine plus isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure. Br. Heart J., 56, 12-28.
17. DARFLER, E.J., MAHAN, L.C., KOACHMAN, A.M. & INSEL, P.A. (1982). Stimulation by forskolin of intact S49 lymphoma cells involves the nucleotide regulatory protein of adenylate cyclase. J. Biol. Chem., 257, 11901-11907.
18. FRANCIS, G.S., COHN, J.N., JOHNSON, G., RECTOR, T.S., GOLDMAN, S. & SIMON, A. (1993). Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation, 87 (suppl VI), VI-40-VI-48.
19. GANTEN, D (1993). The renin-angiotensin paradigm. Practical therapeutical consequences of basic research. Drug Res., 43, 191-196.
20. GANTEN, D., TAKAHASHI S., LINDPAINTNER K., & MULLINS, J. (1991). Genetic basis of hypertension. The renin-angiotensin paradigm. Hypertension, 18, (suppl III), III-109-III-114.
21. GARDINER, S.M., MARCH, J.E., KEMP, P.A., MULLINS, J.J. & BENNETT, T. (1995). Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mREN2)27), hypertensive rats. Br. J. Pharmacol., 116, 2237-2244.
22. GOLDSTEIN, D.S. (1983). Plasma catecholamines and essential hypertension. Hypertension, 5, 86-99.
23. GOLDSTEIN, D.S. & KOPIN, I.J. (1990). The autonomic nervous system and catecholamines in normal blood pressure control and in hypertension. In Hypertension: Pathphysiology, Diagnosis and Management, ed. Laragh, J.H & Brenner, B.M. pp. 711-747. New York: Raven Press.
24. GROSSMAN, W., JONES, D. & MCLAURIN, K.P. (1975). Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest., 58, 56-64.
25. HAASS, M., CHENG, B., RICHARDT, G., LANG, R.E. & SCHÖMIG, A. (1989). Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn-Schmiedeberg's Arch. Pharmacol., 339, 71-78.
26. HADCOCK, J.R. & MALBON, C.C. (1993). Agonist regulation of gene expression of adrenergic receptors and G-proteins. J. Neurochem., 60, 1-9.
27. HAUSDORFF, W.P., CARON, M.G. & LEFKOWITZ, R.J. (1990). Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J., 4, 2881-2889.
28. HILGERS, K.F. PETERS, J., VEELKEN, R., SOMMER, M., RUPPRECHT, G., GANTEN, D., LUFT, F.C. & MANN, J.F.E. (1992). Increased vascular angiotensin formation in female rats harbouring the mouse Ren-2 gene. Hypertension, 19, 687-691.
29. KANNEL, W.B., CASTELLI, W.P. MCNAMARA, P.M., MCKEE, P.A. & FEINLEIB, M. (1972). Role of blood pressure in the development of the congestive heart failure. The Framingham study. N. Engl. J. Med., 287, 781-787.
30. LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
31. LARAGH, J.H. & SEALEY, J.E. (1990). The renin-angiotensin-aldosterone system in hypertension dysorders: a key to two forms of arteriolar vasoconstriction and a positive clue to risk of vacular injury (heart attack and stroke) and prognosis. In Hypertension: Pathphysiology, Diagnosis and Management, ed. Laragh, J.H. & Brenner, B.M. pp. 1329-1348. New York: Raven Press.
32. LEVY, D. (1988). Left ventricular hypertrophy. Epidemiological insights from the Framingham heart study. Drugs, (suppl 5), 1-5.
33. LI, C., PRAKASH, O & RE, R.N. (1989). Altered regulation of angiotensin gene expression in left ventricles of hypertensive rats. Circulation, 80 (suppl. II), II-616.
34. LINDPAINTNER, K., JIN, M., NIEDERMAIER, N., WILHELM, M.J. & GANTEN, D. (1990). Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ. Res., 67, 564-573.
35. LINZ, W., HENNING, R. & SCHÖLKENS, B.A. (1991). Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy. J. Hypertens., 9 (suppl 6), S400-S401.
36. LINZ, W., SCHÖLKENS, B.A. & GANTEN, D. (1989). Converting enzyme inhibition prevents the development and induces regression of cardiac hypertrophy in rats. Clin. Exp. Hypertens., A11, 1325-1350.
37. MAJEWSKI, H., HEDLER, L., SCHNURR, C. & STARKE, K. (1984). Modulation of noradrenaline release in the pithed rabbit: a role for angiotensin II. J. Cardiovasc. Pharmacol., 6, 888-869.
38. MALIK, K.U. & NASJLETTI, A (1976). Facilitation of adrenergic transmission by locally generated angiotensin II in rat mensenteric arteries. Circ. Res., 38, 26-30.
39. MANCIA, G., SAINO, A. & GRASSI, G. (1995). Interactions between the sympathetic nervous system and the renin angiotensin system. In Hypertension: Pathphysiology, Diagnosis and Management, ed. Laragh, J.H & Brenner, B.M. pp 399-407. New York: Raven Press.
40. MCDONALD, K.M., MOCK, J., D'ALOIA, A., PARRISH, T., HAUER, K., FRANCIS, G., STILLMAN, A. & COHN, J.N. (1995). Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation, 91, 2043-2048.
41. MIYAZAKI, M., OKAMOURA, T., OKUNISHI, H. & TODA, N. (1987). Possible role of vascular angiotensin-converting enzyme in the genesis of hypertension. Clin. Exp. Hypertens., 9, 435-440.
42. MULLINS, J.J., PETERS, J. & GANTEN, D. (1990). Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature, 344, 541-544.
43. NAGANO, M., NAKAMURA, M., TABUCHI, Y., RAGUKI, H., HIGASHIMORI, K., KATAHIRA, K., TSUNETOSHI, T., OTSUKA, A., HIGAKI, J., MIKAMI, T. & OGIHARA, T. (1990). Role of cardiac angiotensin II in left ventricular hypertrophy of spontaneously hypertensive rats. Circulation, 82 (supp. II), II-616.
44. PARAN, E., NEMENOFF, R.A. & SCHRIER, R.W. (1995). Role of the renin-angiotensin system in essential hypertension. Curr. Opin. Nephrol. Hypertens., 4, 295-299.
45. PFEFFER, J.M., PFEFFER, M.A. & FROHLICH, E.D (1971). Validity of an indirect tail-cuff method of determining systolic arterial pressure in unanesthetized mormotensive and spontaneously hypertensive rats. J. Lab. Clin. Med., 78, 957-962.
46. RUZICKA, M., YUAN, B., HARMSEN, E. & LEENEN, F.H.H. (1993). The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation, 87, 927-930.
47. SADOCHIMA, J. & IZUMO, S. (1993). Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia in cardiac fibroblasts. Circ. Res., 87, 921-930.
48. SALOMON, Y., LONDOS, C. & RODBELL, M. (1974). A highly sensitive adenylate cyclase assay. Annal. Biochem., 58, 541-548.
49. SCHUNKERT, H., DZAU, V.J., TANG, S.S., HIRSCH, A.T., APSTEIN, C & LORELL, B. (1990). Increased rat angiotensin converting enzyme activity and mRNA-levels in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility and relaxation. J. Clin. Invest., 86, 535-539.
50. SCHUNKERT, H., INGELFINGER, J.H., HIRSCH, A.T., PINTO, Y., REMME, H.J. & DZAU, V.J. (1993). Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ. Res., 72, 312-318.
51. SCHWIELER, J.H. & HJEMDAHL, P. (1992). Influence of angiotensin-converting enzyme inhibition on sympathetic neurotransmission: possible roles of bradykinin and prostaglandins. J. Cardiovasc. Pharmacol., 20 (suppl 9), S39-S46.
52. SEAMON, K.B., PADGETT, W & DALY, J.W. (1981). Forskolin: unique diterpene activator of adenylyl cyclase in membranes and in intact cells. Proc. Natl. Acad. Sci. U.S.A., 78, 3363-3367.
53. SIMPSON, P. (1983). Norepinephrine stimulated hypertrophy of cultured rat myocardial cells is an α1-adrenergic response. J. Clin. Invest., 72, 732-738.
54. STUDER, R., REINECKE, H., MÜLLER, B., HOLTZ, J. & DREXLER, H. (1994). Increased angiotensin I converting enzyme gene expression in the failing human heart: quantification by competitive polymerase chain reaction. J. Clin. Invest., 94, 301-310.
55. SWARTZ, S.L., WILLIAMS, G.H. & HOLLENBERG, N.K. (1980). Captopril induced changes in prostaglandin production. J. Clin. Invest., 65, 1257-1264.
56. TAUSSIG, R., INIGUEZ-LLUHI, J.A. & GILMAN, A.G. (1993). Inhibition of adenylyl cyclase by Giα. Science, 261, 218-221.
57. TSOPORIS, J. & LEENEN, F.H.H. (1988). Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension, 11, 376-386.
58. URATA, H., NISHIMURA, H. & GANTEN, D. (1995). Mechanisms of angiotensin II formation in humans. Eur. Heart J., 16 (suppl N), 79-85.
59. WALLENSTEIN, S., ZUCKER, C.L. & FLEISS, J.L. (1980). Some statistical methods useful in circulation research. Circ. Res., 47, 1-9.
60. WEBER, K.T. & BRILLA, C.G. (1983). Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation, 83, 1849-1865.
61. WEBER, K.T. & BRILLA, C.G. (1992). Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res. Cardiol., 87 (suppl 7), 291-301.